Skip to main content
SpringerLink
Log in

Acute Coronary Syndromes

  • Chapter
  • First Online:
Evidence-Based Cardiology Consult

Abstract

Acute coronary syndromes (ACS) are responsible for over 1.4 million hospital admissions in the USA each year and are associated with considerable mortality. ACS encompasses a group of three related clinical entities: unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). A comprehensive description of the definitions and clinical classification of the diseases will be followed by a review of disease pathophysiology. The role of inflammation, endothelial dysfunction, and plaque vulnerability and rupture are presented. The ability to rapidly and accurately diagnose ACS is paramount to patient care as early initiation of therapy improves outcomes. The diagnostic criteria will be covered including methods of clinical risk stratification. The treatment of ACS has evolved rapidly over the last 10 years, with a focus on achieving timely reperfusion in STEMI and the approval of several new antiplatelet and antithrombin therapies. This chapter will provide a categorized review of medical treatment options and interventional strategies for ACS and guide clinicians in determining appropriate patients for invasive therapies. Additionally, a review of recently published ACS guidelines will be provided.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 159.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 209.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Braunwald E. Unstable angina. A classification. Circulation. 1989;80(2):410–4.

    PubMed  CAS  Google Scholar 

  2. Scirica BM, Cannon CP, McCabe CH, et al. Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification. Am J Cardiol. 2002;90:821–6.

    PubMed  Google Scholar 

  3. Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188–97.

    PubMed  Google Scholar 

  4. Lloyd-Jones D, Adams R, Carnethon M, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–6.

    PubMed  Google Scholar 

  5. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326(5):310–8.

    PubMed  CAS  Google Scholar 

  6. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 2001;104(3):365–72.

    PubMed  CAS  Google Scholar 

  7. Sullivan E, Kearney M, Isner JM, et al. Pathology of unstable angina: analysis of biopsies obtained by directional coronary atherectomy. J Thromb Thrombolysis. 1994;1(1):63–71.

    PubMed  Google Scholar 

  8. Mizuno K, Satumo K, Miyamoto A, et al. Angioscopic evaluation of coronary artery thrombi in acute coronary syndromes. N Engl J Med. 1992;326(5):287–91.

    PubMed  CAS  Google Scholar 

  9. Chen L, Chester MR, Crook R, Kaski JC. Differential progression of complex culprit stenoses in patients with stable and unstable angina pectoris. J Am Coll Cardiol. 1996;28(3):597–603.

    PubMed  CAS  Google Scholar 

  10. Little WC, Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157–66.

    PubMed  CAS  Google Scholar 

  11. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: a three-vessel intravascular ultrasound study. Circulation. 2002;106(7):804–8.

    PubMed  CAS  Google Scholar 

  12. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2007;50(7):e1–157.

    PubMed  Google Scholar 

  13. Summers RL, Cooper GJ, Carlton FB, et al. Prevalence of atypical chest pain descriptions in a population from the southern United States. Am J Med Sci. 1999;318(3):142–5.

    PubMed  CAS  Google Scholar 

  14. Pope JH, Ruthazer R, Beshansky JR, et al. Clinical features of emergency department patients presenting with symptoms suggestive of acute cardiac ischemia: a multicenter study. J Thromb Thrombolysis. 1998;6(1):63–74.

    PubMed  Google Scholar 

  15. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management, AHCPR Publication No. 94-0602. Rockville: Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, US Public Health Service, US Department of Health and Human Services; 1994.

    Google Scholar 

  16. Henrikson CA, Howell EE, Bush DE, et al. Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med. 2003;139:979–86.

    PubMed  Google Scholar 

  17. Jayes Jr RL, Beshansky JR, D’Agostino RB, Selker HP. Do patients’ coronary risk factor reports predict acute cardiac ischemia in the emergency department? A multicenter study. J Clin Epidemiol. 1992;45(6):621–6.

    PubMed  Google Scholar 

  18. Pryor DB, Shaw L, McCants CB, et al. Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med. 1993;118(2):81–90.

    PubMed  CAS  Google Scholar 

  19. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2004;110(5):588–636.

    PubMed  Google Scholar 

  20. Cannon CP, McCabe CH, Stone PH, et al. The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III Registry ECG Ancillary Study. Thrombolysis in Myocardial Ischemia. J Am Coll Cardiol. 1997;30(1):133–40.

    PubMed  CAS  Google Scholar 

  21. Manari A, Albiero R, De Servi S. High-risk non-ST-segment elevation myocardial infarction versus ST-segment elevation myocardial infarction: same behaviour and outcome? J Cardiovasc Med. 2009;10 Suppl 1:S13–6.

    Google Scholar 

  22. Savonitto S, Ardissino D, Granger CB, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA. 1999;281(8):707–13.

    PubMed  CAS  Google Scholar 

  23. Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338(21):1488–97.

    Google Scholar 

  24. Brush YE, Brand DA, Acamporci D, et al. Use of the initial electrocardiogram to predict in-hospital complications of acute myocardial infarction. N Engl J Med. 1985;312:1137–41.

    PubMed  Google Scholar 

  25. Slater DK, Hlatky MA, Mark DB, et al. Outcome in suspected acute myocardial infarction with normal or minimally abnormal admission electrocardiographic findings. Am J Cardiol. 1987;60:766–70.

    PubMed  CAS  Google Scholar 

  26. Boden WE, Kleiger RE, Gibson RS, et al. Favourable long term prognosis in patients with non-Q wave acute myocardial infarction not associated with specific electrocardiographic changes. Br Heart J. 1989;61:396–402.

    PubMed  CAS  Google Scholar 

  27. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined–a consensus document Of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36(3):959–69.

    PubMed  CAS  Google Scholar 

  28. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Circulation. 2007;116:2634–53.

    PubMed  Google Scholar 

  29. Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000;140(6):917–27.

    PubMed  CAS  Google Scholar 

  30. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335(18):1342–9.

    PubMed  CAS  Google Scholar 

  31. Shapiro BP, Babuin L, Jaffe AS. Cardiac biomarkers. In: Murphy JG, Lloyd MA, editors. Mayo clinic cardiology: concise textbook. 3rd ed. Rochester/Boca Raton: Mayo Clinic Scientific Press and New York/Informa Healthcare; 2007. p. 773–80.

    Google Scholar 

  32. Sabatine MS, Antman EM. The thrombolysis in myocardial infarction risk score in unstable angina/non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2003;41(S):89S–95.

    PubMed  Google Scholar 

  33. Eagle KA, Lim MJ, Dabbous OH, et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month post discharge death in an international registry. JAMA. 2004;291:2727–33.

    PubMed  CAS  Google Scholar 

  34. de Araujo GP, Ferreira J, Aguiar C, et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. 2005;26:865–72.

    Google Scholar 

  35. Antman EM, Cohen M, Bernink PJ, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA. 2000;284:835–42.

    PubMed  CAS  Google Scholar 

  36. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable angina/Non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):e215–367.

    PubMed  Google Scholar 

  37. Kushner FG, Hand M, Smith Jr SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction and ACC/AHA/SCAI guidelines on percutaneous coronary intervention a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54(23):2205–41.

    PubMed  Google Scholar 

  38. Théroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med. 1988;319(17):1105–11.

    PubMed  Google Scholar 

  39. Group RISC. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336(8719):827–30.

    Google Scholar 

  40. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA. 1996;276(10):811–5.

    PubMed  CAS  Google Scholar 

  41. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8):2710–5.

    PubMed  CAS  Google Scholar 

  42. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007;131(6):1644–7.

    PubMed  Google Scholar 

  43. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330–5.

    PubMed  CAS  Google Scholar 

  44. Swahn E, Wallentin L. Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC study group. Am J Cardiol. 1997;80(5A):25E–9.

    PubMed  CAS  Google Scholar 

  45. Petersen JL, Mahaffey KW, Hasselblad V, et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST- segment elevation acute coronary syndromes: a systematic overview. JAMA. 2004;292(1):89–96.

    PubMed  CAS  Google Scholar 

  46. Cohen M, Demers C, Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med. 1997;337(7):447–52.

    PubMed  CAS  Google Scholar 

  47. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100(15):1593–601.

    PubMed  CAS  Google Scholar 

  48. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292(1):45–54.

    PubMed  CAS  Google Scholar 

  49. de Lemos JA, Blazing MA, Wiviott SD, A to Z Investigators, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the a phase of the A-to-Z trial. Eur Heart J. 2004;25(19):1688–94.

    PubMed  Google Scholar 

  50. Califf RM, Petersen JL, Hasselblad V, et al. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. Am Heart J. 2005;149(4 Suppl):S91–9.

    PubMed  CAS  Google Scholar 

  51. de Lemos JA, Rifai N, Morrow DA, et al. Elevated baseline myoglobin is associated with increased mortality in acute coronary syndromes, even among patients with normal baseline troponin I: a TIMI 11B substudy. Circulation. 1999;100(suppl I):I372–3.

    Google Scholar 

  52. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477–88.

    PubMed  CAS  Google Scholar 

  53. Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J. 2007;28:2077–86.

    PubMed  CAS  Google Scholar 

  54. Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet. 2011;378(9792):693–703.

    PubMed  CAS  Google Scholar 

  55. Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost. 2011;9:1902–15.

    PubMed  CAS  Google Scholar 

  56. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006;354(14):1464–76.

    PubMed  CAS  Google Scholar 

  57. MICHELANGELO OASIS-5 Steering Committee, Mehta SR, Yusuf S, Granger CB, et al. Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. Am Heart J. 2005;150(6):1107.

    PubMed  Google Scholar 

  58. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006;295:1519–30.

    PubMed  CAS  Google Scholar 

  59. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631–7.

    Google Scholar 

  60. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911–21.

    PubMed  CAS  Google Scholar 

  61. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet. 1999;353:429–38.

    Google Scholar 

  62. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853–63.

    PubMed  CAS  Google Scholar 

  63. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203–16.

    PubMed  CAS  Google Scholar 

  64. Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet. 2007;369:907–19.

    PubMed  CAS  Google Scholar 

  65. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218–30.

    PubMed  CAS  Google Scholar 

  66. Kastrati A, Neumann F, Schulz S, et al. Abciximab and heparin versus bivalirudin for non–ST-elevation myocardial infarction. N Engl J Med. 2011;365:1980–9.

    PubMed  Google Scholar 

  67. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193–204.

    PubMed  CAS  Google Scholar 

  68. The Direct Thrombin Inhibitor Trialists’ Collaborative Group. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients’ data. Lancet. 2002;359:294–302.

    Google Scholar 

  69. Lewis HD, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med. 1983;309(7):396–403.

    PubMed  Google Scholar 

  70. Cairns JA, Gent M, Singer J, et al. Aspirin, sulfinpyrazone, or both in unstable angina; results of a Canadian multicenter trial. N Engl J Med. 1985;313(22):1369–75.

    PubMed  CAS  Google Scholar 

  71. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994; 308(6921):81–106.

    Google Scholar 

  72. Alexander JH, Harrington RA, Tuttle RH, et al. Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol. 1999;83(8):1147–51.

    PubMed  CAS  Google Scholar 

  73. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al. Aspirin resistance: position paper of the working group on aspirin resistance. J Thromb Haemost. 2005;3(6):1309–11.

    PubMed  CAS  Google Scholar 

  74. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367(9510):606–17.

    PubMed  CAS  Google Scholar 

  75. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

    Google Scholar 

  76. The CURRENT-OASIS Investigators. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930–42.

    Google Scholar 

  77. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation. 2003;108(14):1682–7.

    PubMed  CAS  Google Scholar 

  78. Silber S, Albertsson P, Avilés FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005;26(8):804–47.

    PubMed  Google Scholar 

  79. Love BB, Biller J, Gent M. Adverse haematological effects of ticlopidine. Prevention, recognition and management. Drug Saf. 1998;19:89–98.

    PubMed  CAS  Google Scholar 

  80. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in un- stable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell’Angina Instabile Group. Circulation. 1990;82(1):17–26.

    PubMed  CAS  Google Scholar 

  81. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998;98(20):2126–32.

    PubMed  CAS  Google Scholar 

  82. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    PubMed  CAS  Google Scholar 

  83. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–33.

    PubMed  CAS  Google Scholar 

  84. Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2005;111:2099–106.

    PubMed  CAS  Google Scholar 

  85. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–89.

    PubMed  CAS  Google Scholar 

  86. Sabatine MS, Cannon CP, Gibson CM, et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics. The PCI-CLARITY study. JAMA. 2005;294:1224–32.

    PubMed  CAS  Google Scholar 

  87. Oqueli E, Hiscock M, Dick R. Clopidogrel resistance. Heart Lung Circ. 2007;16 Suppl 3:S17–28.

    PubMed  Google Scholar 

  88. Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006;47(1):27–33.

    PubMed  CAS  Google Scholar 

  89. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107(23):2908–13.

    PubMed  Google Scholar 

  90. Müller I, Besta F, Schulz C, et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003;89(5):783–7.

    PubMed  Google Scholar 

  91. Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849–57.

    PubMed  CAS  Google Scholar 

  92. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.

    PubMed  CAS  Google Scholar 

  93. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G > a polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51:1925–34.

    PubMed  CAS  Google Scholar 

  94. Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol. 2005;45(8):1157–64.

    PubMed  CAS  Google Scholar 

  95. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug ‘resistance’. Part 1: mechanisms and clinical measurements. Nat Rev Cardiol. 2009;6(4):273–82.

    PubMed  CAS  Google Scholar 

  96. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097–105.

    PubMed  CAS  Google Scholar 

  97. O’Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989–97.

    PubMed  Google Scholar 

  98. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909–17.

    PubMed  CAS  Google Scholar 

  99. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol. 2010;56:2051–66.

    PubMed  Google Scholar 

  100. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

    PubMed  CAS  Google Scholar 

  101. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON- TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353–63.

    PubMed  CAS  Google Scholar 

  102. Murphy SA, Antman EM, Wiviott SD, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON- TIMI 38 trial. Eur Heart J. 2008;29(20):2473–9.

    PubMed  CAS  Google Scholar 

  103. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation. 2009;119:2553–60.

    PubMed  CAS  Google Scholar 

  104. Varenhorst C, James S, Erlinge D, et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur Heart J. 2009;30:1744–52.

    PubMed  CAS  Google Scholar 

  105. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

    PubMed  CAS  Google Scholar 

  106. Ticagrelor [package insert]. London, UK: AstraZeneca. Available at: www.brillinta.com. Accessed 31 Jan2012.

  107. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9431):331–7.

    PubMed  CAS  Google Scholar 

  108. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. Circulation. 1997;96(5):1445–53.

    Google Scholar 

  109. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338(21):1498–505.

    Google Scholar 

  110. Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in preventing ischemic complications. J Am Coll Cardiol. 1997;30(1):149–56.

    PubMed  CAS  Google Scholar 

  111. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359(9302):189–98.

    PubMed  CAS  Google Scholar 

  112. Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA. 2006;295(13):1531–8.

    PubMed  CAS  Google Scholar 

  113. Hamm CW, Heeschen C, Goldmann B, et al. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. N Engl J Med. 1999;340(21):1623–9.

    PubMed  CAS  Google Scholar 

  114. Heeschen C, Hamm CW, Goldmann B, PRISM Study Investigators. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. Lancet. 1999;354(9192):1757–62.

    PubMed  CAS  Google Scholar 

  115. Théroux P, Alexander Jr J, Pharand C, et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: results from the platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms (PRISM-PLUS) study. Circulation. 2000;102(20):2466–72.

    PubMed  Google Scholar 

  116. Klootwijk P, Meij S, Melkert R, et al. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). Circulation. 1998;98(14):1358–64.

    PubMed  CAS  Google Scholar 

  117. Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes: application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23(3):223–9.

    PubMed  CAS  Google Scholar 

  118. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360:2176–90.

    PubMed  CAS  Google Scholar 

  119. Stone GW, Bertrand ME, Moses JW, et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA. 2007;297:591–602.

    PubMed  CAS  Google Scholar 

  120. Mehta SR, Cannon CP, Fox KA, et al. Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005;293(23):2908–17.

    PubMed  CAS  Google Scholar 

  121. Bavry AA, Kumbhani DJ, Rassi AN, et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48(7):1319–25.

    PubMed  Google Scholar 

  122. Hoenig MR, Doust JA, Aroney CN, Scott IA. Early invasive versus conservative strategies for unstable angina & non-ST- elevation myocardial infarction in the stent era. Cochrane Database Syst Rev. 2006;3, CD004815.

    PubMed  Google Scholar 

  123. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343(8893):311–22.

    Google Scholar 

  124. Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase: clinical findings through hospital discharge. Circulation. 1987;76(1):142–54.

    PubMed  CAS  Google Scholar 

  125. Investigators GUSTO. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673–82.

    Google Scholar 

  126. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354(9180):716–22.

    Google Scholar 

  127. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intra- venous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13–20.

    PubMed  Google Scholar 

  128. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283(22):2941–7.

    PubMed  CAS  Google Scholar 

  129. ASSENT-4 PCI investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367(9510):569–758.

    Google Scholar 

  130. Ellis SG, Armstrong P, Betriu A, et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the facilitated intervention with enhanced reperfusion speed to stop events (FINESSE) trial. Am Heart J. 2004;147(4):E16.

    PubMed  Google Scholar 

  131. Wijeysundera HC, Vijayaraghavan R, Nallamothu BK, et al. Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for ST-segment myocardial infarction: a meta-analysis of randomized trials. J Am Coll Cardiol. 2007;49:422–30.

    PubMed  Google Scholar 

  132. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the combined abciximab reteplase stent study in acute myocardial infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet. 2008;371:559–68.

    PubMed  Google Scholar 

  133. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med. 2009;360:2705–18.

    PubMed  Google Scholar 

  134. Cabello JB, Burls A, Emparanza JI, et al. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev. 2010;(6):CD007160.

    Google Scholar 

  135. Moradkhan R, Sinoway LI. Revisiting the role of oxygen therapy in cardiac patients. J Am Coll Cardiol. 2010;56(13):1013–6.

    PubMed  Google Scholar 

  136. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1622–32.

    PubMed  CAS  Google Scholar 

  137. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711–8.

    PubMed  CAS  Google Scholar 

  138. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. N Engl J Med. 2004;350(15):1495–504.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Interventional Cardiology Fellow, Department of Medicine, Cardiology, Brown Medical School, 593 Eddy Street, Providence, RI, 02903, USA

    Gabriel A. Delgado MD

  2. Department of Medicine, Division of Cardiology, Brown Medical School, Rhode Island Hospital, 593 Eddy Street, Providence, RI, 02903, USA

    J. Dawn Abbott MD

Authors
  1. Gabriel A. Delgado MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Dawn Abbott MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Dawn Abbott MD .

Editor information

Editors and Affiliations

  1. Division of Cardiology, Department of Medicine,, Stony Brook University, School of Medicine,, Stony Brook, USA

    Kathleen Stergiopoulos

  2. Division of Cardiology, Stony Brook University, Stony Brook, New York, USA

    David L. Brown

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag London

About this chapter

Cite this chapter

Delgado, G.A., Abbott, J.D. (2014). Acute Coronary Syndromes. In: Stergiopoulos, K., Brown, D. (eds) Evidence-Based Cardiology Consult. Springer, London. https://doi.org/10.1007/978-1-4471-4441-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4441-0_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4440-3

  • Online ISBN: 978-1-4471-4441-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation